TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20663460

Group type: EXPERIMENTAL
Intervention: Postprandial (PP) SMBG results to adjust morning medication
Number of subjects: 280

Group type: COMPARATOR
Intervention: Fasting/preprandial (FP) SMBG results to adjust evening medication
Number of subjects: 280
Study: 19726355

Group type: EXPERIMENTAL
Intervention: Standardized SIT for 12 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Inhaled corticosteroids according to GINA
Number of subjects: 65
Study: 15929503

Group type: EXPERIMENTAL
Intervention: Oswestry Standing Frame (n = 71)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual stroke unit care (Control group, n = 69)
Number of subjects: 140
Study: 12551705

Group type: EXPERIMENTAL
Intervention: Sigmasporin Microoral
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sandimmun Neoral
Number of subjects: 30
Study: 10608205

Group type: EXPERIMENTAL
Intervention: Continuous epidural block with mepivacaine 1.5% initiated 20 min before surgical incision (Pre group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous epidural block with mepivacaine 1.5% initiated at completion of surgery (Post group)
Number of subjects: 70
Study: 7851604

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) continued use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leuprolide acetate (LA) stopped after 5 days
Number of subjects: 0
Study: 1951905

Group type: EXPERIMENTAL
Intervention: Local gentamicin and drainage (Group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Drainage alone (Group B)
Number of subjects: 44
Study: 7007179

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulfate
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 30430294

Group type: EXPERIMENTAL
Intervention: Jugular vein access
Number of subjects: 49

Group type: COMPARATOR
Intervention: Femoral vein access
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Femoral vein access by non-expert operators
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 29866644

Group type: EXPERIMENTAL
Intervention: Digital health intervention using electronic inhaler sensors and a digital health platform for asthma management.
Number of subjects: 207
Study: 27206266

Group type: EXPERIMENTAL
Intervention: Mephedrone 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MDMA 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24440204

Group type: EXPERIMENTAL
Intervention: Paper Medical Record (PMR)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Electronic Medical Record (EMR)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Both PMR and EMR
Number of subjects: 160

Group type: COMPARATOR
Intervention: EMR
Number of subjects: 160
Study: 23020711

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 20566676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: 2.5 mg dapagliflozin
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: 5 mg dapagliflozin
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin
Number of subjects: 485
Study: 17392542

Group type: EXPERIMENTAL
Intervention: Cinnamon (1 g/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 16219189

Group type: EXPERIMENTAL
Intervention: Royal jelly
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 11863124

Group type: EXPERIMENTAL
Intervention: Intravenous iron supplementation (100 mg every 2 weeks or 1 month)
Number of subjects: 149
Study: 10424314

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg 3 times daily for 1 year)
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Standard treatment alone (control group)
Number of subjects: 1027
Study: 7591280

Group type: EXPERIMENTAL
Intervention: FEC+GM-CSF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FEC+G-CSF
Number of subjects: 30
Study: 2245919

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation intervention group
Number of subjects: 767

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed)
Number of subjects: 767
Study: 7214785

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29397442

Group type: EXPERIMENTAL
Intervention: Aromatherapy during the first stage of labor
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard obstetric care (Control group)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 104
Study: 27134066

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-Eye Movement Desensitization and Reprocessing (Control)
Number of subjects: 56
Study: 24622423

Group type: EXPERIMENTAL
Intervention: Nonconcurrent rehabilitation (N‐CON)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Concurrent rehabilitation (CON)
Number of subjects: 11
Study: 24032205

Group type: EXPERIMENTAL
Intervention: Auricular point magnetic sticking (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: In-pair sticking of magnetic beads at front-back acupoints (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 120
Study: 20492074

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap plus connective tissue graft (CAF+CTG)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) alone
Number of subjects: 13
Study: 18710446

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 492

Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 492
Study: 16466168

Group type: EXPERIMENTAL
Intervention: Western medicinal treatment (WM) with additional medication of CHM (modified Huxin Recipe)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional Western medicinal treatment (WM)
Number of subjects: 106
Study: 12645801

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b at 5 MU daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-alpha-2b at 3 MU three times a week (control)
Number of subjects: 0
Study: 11192960

Group type: EXPERIMENTAL
Intervention: Salbutamol (100 microg) via Easyhaler at a target inspiratory flow of 30 l min(‐1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Salbutamol (100 microg) via pressurised metered‐dose inhaler (pMDI) plus spacer
Number of subjects: 21
Study: 9170564

Group type: EXPERIMENTAL
Intervention: Single task SRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual task SRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRT (motor-linked test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pattern judgment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generation test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit knowledge test
Number of subjects: 0
Study: 1416159

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl infusion
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravenous fentanyl infusion
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 4019944

Group type: EXPERIMENTAL
Intervention: Diet with P/S ratio 1.3
Number of subjects: 14

Group type: COMPARATOR
Intervention: Diet with P/S ratio 0.7
Number of subjects: 14
Study: 30513433

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation combined with lifestyle intervention (LI) for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lifestyle intervention (LI) alone
Number of subjects: 70
Study: 29422091

Group type: EXPERIMENTAL
Intervention: Partially supervised exercise intervention with individual counselling to increase vigorous physical activity (PA) by at least 3 hours per week, daily PA documentation, step counter, and monthly phone calls for the first 6 months.
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Partially supervised exercise intervention with motivational feedback.
Number of subjects: 292

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 292
Study: 27106715

Group type: EXPERIMENTAL
Intervention: Cannabis administration
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cocaine administration
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 61
Study: 24827934

Group type: EXPERIMENTAL
Intervention: Suppression instruction
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Acceptance instruction
Number of subjects: 64

Group type: COMPARATOR
Intervention: No-regulation (Control) instruction
Number of subjects: 64
Study: 21904224

Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HTS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 20
Study: 20091678

Group type: EXPERIMENTAL
Intervention: LB80380 (30, 60, 90, 150, 240 mg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: LB80380
Number of subjects: 65
Study: 18166199

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) at 30 mg/kg/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) at 20 mg/kg/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) at 40 mg/kg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (1 control fibroblast cell line)
Number of subjects: 33
Study: 16182221

Group type: EXPERIMENTAL
Intervention: CT-ultrasound fusion brachytherapy
Number of subjects: 54
Study: 12574567

Group type: EXPERIMENTAL
Intervention: Stroke patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 10476888

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 85
Study: 8558634

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (200 micrograms subcutaneously once a week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Interleukin-2 and interferon-alpha 2b (4 x 4.8 x 10(6) IU/m.2 interleukin-2 subcutaneously on days 1 and 22, 2 x 4.8 x 10(6) IU/m.2 on days 2 and 23, and 2 x 2.4 x 10(6) IU/m.2 combined with interferon-alpha 2b subcutaneously at 3 x 10(6) IU/m.2 on days 3, 5, 24 and 26, and 6 x 10(6) IU/m.2 3 times weekly for 6 weeks)
Number of subjects: 30
Study: 1831394

Group type: EXPERIMENTAL
Intervention: Isradipine (ISR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 20
Study: 6361228

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 0.7 mg/kg orally administered
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydroxyzine 0.7 mg/kg three times daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydroxyzine 1.4 mg/kg three times daily
Number of subjects: 12
Study: 31753781

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion
Number of subjects: 53
Study: 30833204

Group type: EXPERIMENTAL
Intervention: Video coaching using Google Glass (intervention group, 20 participants)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Verbal coaching alone (control group, 22 participants)
Number of subjects: 42
Study: 30392581

Group type: EXPERIMENTAL
Intervention: Brain specific fatty acid (BSFA) supplementation (DHA and ArA) during pregnancy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 86
Study: 26893551

Group type: EXPERIMENTAL
Intervention: Tiotropium + olodaterol (5/5 µg and 2.5/5 µg) via Respimat(®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol + fluticasone propionate (50/500 µg and 50/250 µg) via Accuhaler(®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium + olodaterol
Number of subjects: 0
Study: 24535560

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22985134

Group type: EXPERIMENTAL
Intervention: 4 weeks of treatment with one of 5 different dosing combinations (2 or 3 30-min treatments per week or 1, 2, or 3 60-min treatments per week)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 6 weekly 60-min massages
Number of subjects: 228

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 228
Study: 20194546

Group type: EXPERIMENTAL
Intervention: Bifrontal electrode placement at one and a half times seizure threshold
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Bitemporal electrode placement at one and a half times seizure threshold
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Right unilateral electrode placement at six times seizure threshold
Number of subjects: 230
Study: 22858527

Group type: EXPERIMENTAL
Intervention: Ozone/Reductant/Patient Kit
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Reductant/Patient Kit
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fluoride free toothpaste (Control)
Number of subjects: 14
Study: 16429658

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily for 6 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Finasteride 5 mg daily for 6 weeks
Number of subjects: 21
Study: 12630022

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1, methylprednisolone, and C-tube drainage
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 and steroid administration
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Postoperative management with steroid, prostaglandin E1, and C-tube drainage
Number of subjects: 13
Study: 10226860

Group type: EXPERIMENTAL
Intervention: Captopril plus diuretics
Number of subjects: 345

Group type: COMPARATOR
Intervention: Digoxin plus diuretics
Number of subjects: 345
Study: 8764421

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (Aterax) 1‐2 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydroxyzine and Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Premedication visit
Number of subjects: 60
Study: 1860324

Group type: EXPERIMENTAL
Intervention: Standard doses of epinephrine (1 mg iv every 5 mins)
Number of subjects: 15
Study: 6354248

Group type: EXPERIMENTAL
Intervention: Reality orientation therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Diversional occupational therapy
Number of subjects: 38
Study: 29426956

Group type: EXPERIMENTAL
Intervention: Brief advice based on risk communication by a nurse counselor
Number of subjects: 528

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 528
Study: 29075381

Group type: EXPERIMENTAL
Intervention: milestones plus a 13‐item checklist with behavioral anchors
Number of subjects: 20

Group type: COMPARATOR
Intervention: milestones alone
Number of subjects: 20
Study: 25569274

Group type: EXPERIMENTAL
Intervention: BB-12-supplemented yogurt
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control yogurt (non-supplemented)
Number of subjects: 40
Study: 23975236

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (60 μg/m(2)/wk) plus oral ribavirin (15 mg/kg/day)
Number of subjects: 107
Study: 20937312

Group type: EXPERIMENTAL
Intervention: 60 μg YIC therapeutic vaccine
Number of subjects: 242

Group type: COMPARATOR
Intervention: Alum immunized control group
Number of subjects: 242
Study: 18582568

Group type: EXPERIMENTAL
Intervention: Diclofenac extended release (ER) tablet using the novel dissolution test apparatus
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diclofenac extended release (ER) tablet using the conventional dissolution apparatus (USP II)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Plasma concentration versus time profiles after the administration of an ER tablet
Number of subjects: 24
Study: 16904536

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 2727

Group type: COMPARATOR
Intervention: LOCM
Number of subjects: 2727

Group type: EXPERIMENTAL
Intervention: Iodixanol in CKD patients
Number of subjects: 2727

Group type: COMPARATOR
Intervention: LOCM in CKD patients
Number of subjects: 2727

Group type: EXPERIMENTAL
Intervention: Iodixanol in CKD + DM patients
Number of subjects: 2727

Group type: COMPARATOR
Intervention: LOCM in CKD + DM patients
Number of subjects: 2727
Study: 12952230

Group type: EXPERIMENTAL
Intervention: EBVD chemotherapy
Number of subjects: 264

Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 264
Study: 11113043

Group type: EXPERIMENTAL
Intervention: Elective stent implantation
Number of subjects: 735

Group type: COMPARATOR
Intervention: Guided PTCA
Number of subjects: 735
Study: 9025802

Group type: EXPERIMENTAL
Intervention: 600 mg of slow release caffeine (SRC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 1815019

Group type: EXPERIMENTAL
Intervention: Pre-brushing mouthrinse used according to manufacturer's instructions
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal oral hygiene practices (Control)
Number of subjects: 41
Study: 6636394

Group type: EXPERIMENTAL
Intervention: Prophylactic antimicrobial therapy (sulfamethoxazole)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no prophylactic antimicrobial therapy)
Number of subjects: 78
Study: 29994980

Group type: EXPERIMENTAL
Intervention: Lowest CBT (32.0-36.2°C)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Middle CBT (36.3-36.8°C)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Highest CBT (36.9-38.8°C)
Number of subjects: 99
Study: 27400015

Group type: COMPARATOR
Intervention: 12 mL of a 1% lidocaine paracervical block
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 20 mL of a self-administered, 2% lidocaine gel
Number of subjects: 142
Study: 24886960

Group type: EXPERIMENTAL
Intervention: Social marketing intervention (distribution of HPV vaccination posters and brochures, radio PSAs, online CME training)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control counties (no intervention)
Number of subjects: 194
Study: 22808699

Group type: EXPERIMENTAL
Intervention: 12-week lower-body resistance training program
Number of subjects: 28
Study: 20214831

Group type: EXPERIMENTAL
Intervention: JinQi-Jiangtang tablets (JQJT)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 18406211

Group type: EXPERIMENTAL
Intervention: Proprietary LTG for at least 2 weeks prior to admission
Number of subjects: 9

Group type: COMPARATOR
Intervention: Generic LTG therapy for at least 7 days
Number of subjects: 9
Study: 15745374

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg/daily for 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12115356

Group type: EXPERIMENTAL
Intervention: Azoles antifungal agents (fluconazole, itraconazole, ketoconazole, miconazole)
Number of subjects: 7014
Study: 10195512

Group type: EXPERIMENTAL
Intervention: i.a. bupivacaine (30 mL of 0.25%) + clonidine (1 microg/kg) i.a.
Number of subjects: 50

Group type: COMPARATOR
Intervention: i.a. bupivacaine (30 mL of 0.25%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: i.a. bupivacaine (30 mL of 0.25%) + subcutaneous clonidine (1 microg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: i.a. bupivacaine (30 mL of 0.25%) + epinephrine (5 microg/mL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: clonidine (1 microg/kg) in 30 mL of saline i.a.
Number of subjects: 50
Study: 7559318

Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD) group (n = 90)
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Substance Use Disorder (SUD) group (n = 42)
Number of subjects: 1507

Group type: COMPARATOR
Intervention: Control group (n = 1,189)
Number of subjects: 1507
Study: 2157640

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (intravenous plus oral)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cisplatin (70 mg/m2)
Number of subjects: 37
Study: 377476

Group type: EXPERIMENTAL
Intervention: Erbium169 synoviorthesis
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 7
Study: 31027929

Group type: EXPERIMENTAL
Intervention: PHiD-CV10 vaccine
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control vaccine (hepatitis A or B vaccine)
Number of subjects: 424
Study: 28378139

Group type: EXPERIMENTAL
Intervention: Flippits (distraction cards)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (no distraction)
Number of subjects: 210
Study: 26561617

Group type: EXPERIMENTAL
Intervention: Total fat intake (highest quintile)
Number of subjects: 7038

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid (MUFA) intake (highest quintile)
Number of subjects: 7038

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid (PUFA) intake (highest quintile)
Number of subjects: 7038

Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) intake (highest quintile)
Number of subjects: 7038

Group type: EXPERIMENTAL
Intervention: Trans-fat intake (highest quintile)
Number of subjects: 7038

Group type: EXPERIMENTAL
Intervention: Isocaloric replacement of SFAs with MUFAs and PUFAs
Number of subjects: 7038

Group type: EXPERIMENTAL
Intervention: Isocaloric replacement of trans fat with MUFAs
Number of subjects: 7038

Group type: EXPERIMENTAL
Intervention: PUFA and MUFA intakes
Number of subjects: 7038

Group type: EXPERIMENTAL
Intervention: SFA from pastries and processed foods
Number of subjects: 7038
Study: 23725307

Group type: EXPERIMENTAL
Intervention: Tannase-converted green tea extract (TGE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal green tea extract (NGE)
Number of subjects: 0
Study: 21332729

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor (G-CSF) injection in abdominal skin (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Granulocyte-colony-stimulating factor (G-CSF) injection in lower adipose tissue-containing sites (arms and legs) (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 40
Study: 19746751

Group type: EXPERIMENTAL
Intervention: Otocerum
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Taponoto
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline solution (control group)
Number of subjects: 90
Study: 17692723

Group type: EXPERIMENTAL
Intervention: Tretinoin gel microspheres 0.04%
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Tretinoin gel microspheres 0.1%
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as no treatment)
Number of subjects: 156
Study: 15498085

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77